Patents Examined by Michelle S Horning
  • Patent number: 10648966
    Abstract: A conductive channel-containing membrane includes a membrane layer, and a SPP1 connector polypeptide variant that is incorporated into the membrane layer to form an aperture through which conductance can occur when an electrical potential is applied across the membrane. A method of sensing a molecule, such as a polypeptide or nucleic acid molecule, makes use of the conductive channel-containing membrane. A method of DNA sequence makes use of the conductive channel-containing membrane.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: May 12, 2020
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Peixuan Guo, Shaoying Wang
  • Patent number: 10639370
    Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: May 5, 2020
    Assignees: CONTRAFECT CORPORATION, TRELLIS BIOSCIENCE, LLC
    Inventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
  • Patent number: 10639366
    Abstract: The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: May 5, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Peihong Dai, Weiyi Wang
  • Patent number: 10633636
    Abstract: Disclosed herein is a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One such oncolytic virus is oHSV. One form of TRAIL contained within the oncolytic virus is a secreted form of TRAIL. Examples of various forms of oHSV and secreted TRAIL are disclosed therein. Also disclosed are host cells and therapeutic formulations comprising the recombinant oncolytic virus. Also disclosed are methods of treating cancer in a subject by administering a therapeutic formulation comprising the recombinant oncolytic virus to the subject.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: April 28, 2020
    Assignee: The General Hospital Corporation
    Inventors: Khalid Shah, Kaoru Tamura, Hiroaki Wakimoto
  • Patent number: 10624846
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 21, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10610484
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 7, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10604742
    Abstract: A disposable, virus-trapping membrane, and a corresponding method to remove viruses from solution are described. The membrane includes a disposable, micro-porous filter membrane and a ligand immobilized on the membrane. The ligand irreversibly and selectively binds viruses. The ligand also has a pKa sufficiently high to repel antibodies via electrostatic charge repulsion.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: March 31, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventor: Mark R. Etzel
  • Patent number: 10596112
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: March 24, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10596111
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: March 24, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10590173
    Abstract: A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a polyprotein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polyprotein is also provided.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 17, 2020
    Assignee: Medicago Inc.
    Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Manon Couture, Lucie Poulin, Louis-Philippe Vezina
  • Patent number: 10576114
    Abstract: The present invention relates to a new cocktail of bacteriophages with specific lytic activity against Salmonella enteritidis, Salmonella typhimurium and Salmonella paratyphi B., for reducing, eliminating and/or preventing them in farm animals and animals from the poultry sector, such as poultry, hens and breeding hens, in addition to eggs. It may be administered as an additive in the feed, in water or by spray. Moreover, the cocktail may be used as a disinfectant in work areas of farms and abattoirs, and in processed foods, without affecting the organoleptic properties of the product.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: March 3, 2020
    Assignee: UNIVERSIDAD DE LOS ANDES
    Inventors: Martha Josefina Vives Florez, Ana Paula Jimenez Sanchez, Angela Victoria Holguin Moreno
  • Patent number: 10548930
    Abstract: The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAAE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: February 4, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Jedd Wolchok, Taha Merghoub, Stewart Shuman, Peihong Dai, Weiyi Wang
  • Patent number: 10538786
    Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: January 21, 2020
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico
  • Patent number: 10532107
    Abstract: The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: January 14, 2020
    Assignee: SAIBA GMBH
    Inventors: Martin Bachmann, Andris Zeltins, Paul Pumpens
  • Patent number: 10526376
    Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 7, 2020
    Assignee: University of Copenhagen
    Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
  • Patent number: 10525122
    Abstract: The present invention provides a vaccine containing virus-like particles derived from virus particles having an envelope, in which a lipid-component content of the virus-like particles is reduced relative to a lipid-component content of the virus particles.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: January 7, 2020
    Assignee: KM Biologics Co., Ltd.
    Inventors: Kazuhiko Kimachi, Motoharu Abe, Kazuyuki Ikeda, Hiroto Onuma, Yukari Tsurudome, Daisuke Ikeno, Kiyoto Nishiyama, Tatsufumi Onchi, Yusuke Ooyama, Issay Asano, Ryoichi Kitano
  • Patent number: 10517908
    Abstract: The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: December 31, 2019
    Assignee: ARMATA PHARMACEUTICALS, INC.
    Inventors: Karen Joy Shaw, Sandra P. Morales, Gillian Mearns, Deborah A. Rankin, Frenk Smrekar
  • Patent number: 10519466
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: December 31, 2019
    Assignees: INSTlTUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFlQUE
    Inventors: Frederic Tangy, Clarisse Lorin, Lucile Mollet, Frederic Delebecque
  • Patent number: 10519483
    Abstract: Disclosed herein are methods and systems for rapid detection of microorganisms in a sample, without culturing for enrichment of the microorganism. A modified bacteriophage is also disclosed which comprises a non-native indicator gene in the late gene region. The indicator product is not a fusion protein. The specificity of infectious agents allows a specific microorganism to be targeted, and an indicator signal may be amplified to optimize assay sensitivity.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 31, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Dwight Lyman Anderson, Jose S. Gil, Ben Barrett Hopkins, Stephen Erickson
  • Patent number: 10513551
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: December 24, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low